Events

Neuropore Therapies (NPT™) will present a poster presentation entitled, "Structure based design and synthesis of novel Toll-like Receptor-2 (TLR2) antagonists" on April 30th at the 36th ACS National Medicinal Chemistry SymposiumApril 29th - May 2nd, 2018     Nashville, TN USA

Neuropore Therapies (NPT™) presents at the 2018 Advances in Alzheimer's and Parkinson's Therapies - an AAT-AD/PD Focus Meeting   March 15th, 2018
Torino, Italy 
Click here for more information. 

Neuropore Therapies (NPT™) presents at the 20th Annual American Society for Experimental NeuroTherapeutics (ASENT)  March 8 & 9th, 2018
Rockville, MD USA   Click here for more information. 

Neuropore Therapies (NPT™) will hold an oral presentation at the 6th World CNS Summit entitled, “Targeting Autophagic Protein Clearance Mechanisms for the Treatment of Neurodegenerative Disease.” February 22nd, 2018   
Boston, MA USA   Click here for more information. 


Neuropore Therapies (NPT™) will hold an in-session event at EMBO Conference on Autophagy organizes "Autophagy induction as therapeutics for degenerative disease: A look into drug development of small molecule therapies by biopharmaceutical companies." September 26th, 2017   Cavat-Dubrovnik, Croatia   Click here for more information.

Neuropore Therapies (NPT™) CSO, Dr. Douglas Bonhaus will present a poster at the 2017 EMBO Conference on Autophagy entitled “Upregulation of autophagy for the treatment of Parkinson’s disease and other neurodegenerative diseases” September 26th, 2017   Cavtat-Dubrovnik, Croatia   Click here for more information.

Neuropore Therapies (NPT™) organizes 2016 Society for Neuroscience Satellite Event, "Targeting alpha-synuclein as a disease-modifying treatment for PD & synucleinopathies". November 13, 2016   San Diego, CA    Click here for more information.

Neuropore CEO, Dr. Dieter Meier presented at 10th Congress on Controversies in Neurology. March 17th-20th, 2016

Lisbon, Portugal

Neuropore COO, Dr. Douglas Bonhaus presented at the Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference. November 3rd-4th, 2015

New York, NY

Society for Neuroscience Neuropore researchers presented at the annual Society for Neuroscience Meeting. October 17th-21st, 2015

Chicago, IL

Presentation by Neuropore Founder, Dr. Eliezer Masliah at Grand Challenges in Parkinson’s Disease: A Synucleine. September 30th-October 1st, 2015

Grand Rapids, MI

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the German Society of Neuropathology and Neuroanatomy 60th Annual Meeting. August 26, 2015

Berlin, Germany

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Neuroscience School of Advanced Studies. August 24, 2015

Italy

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Columbia University PDF Center Seminar. August 13, 2015

NY, NY

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Medivation Seminar. August 7, 2015

San Francisco, CA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Banner Alzheimer’s Institute and ASU Biodesign Institute Seminar. July 28, 2015

Phoenix and Tempe AZ

Neuropore Founder and Scientific Advisor, Dr. Eliezer Masliah and CEO and President Dr. Dieter Meier attended the 19th International Congress Of Parkinson’s Disease and Movement Disorders. June 14th-18th, 2015

San Diego, CA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Intl Parkinson’s and Movement Disorders Society 19th Intl Parkinson’s and Movement Disorders Society Congress Understanding and treating proteinopathies. June 16, 2015

San Diego, CA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Intl Parkinson’s and Movement Disorders Society 19th Intl Parkinson’s and Movement Disorders Society Congress. June 16, 2015

San Diego, CA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Michael J. Fox Foundation Meeting. June 8, 2015

New York, NY

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 13th International Symposium. June 5, 2015

San Diego, CA

Neuropore Senior Director of Neuroscience, Dr. Diana Price Participated in Parkinson's Disease Imaging & Biomarkers Roundtable. May 11th-12th, 2015

Montreal, Canada

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the NIH NIA-NACA Meeting. May 12, 2015

Bethesda, MD

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Tulane University Neurosciences Program Seminar Series. April 15, 2015

New Orleans, LA

Neuropore Founder and Scientific Advisor, Dr. Eliezer Masliah and CEO and President Dr. Dieter Meier attended the International Congress on Alzheimer's and Parkinson's Disease. March 18th-22nd, 2015

Nice, France

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 12th International AD-PD conference, Prothena Symposium. March 21, 2015

Nice, France

Presentation by Neuropore Senior Director of Neuroscience, Dr. Diana Price at the World CNS summit: Modeling and Biomarkers. From Bedside to Bench (and back again): Iterative Translation for Improving Therapeutic Development February 17th-19th, 2015

Boston, MA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Mayo Clinic Neurosciences Department Seminar. February 16, 2015

Jacksonville, FL

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the International Parkinson and Movements Disorder Society. Alpha-Synuclein: the Gateway to Parkinsonism. February 13, 2015

Innsbuck, Austria

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the American Academy of Neurology Proteinopathy in Neurodegenerative Diseases. Breakthroughs in Neurology: Translating Today’s Discoveries into Tomorrow’s Clinics. January 23, 2015

Phoenix, AZ

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Cambridge Healthtech Institutes 14th Annual Cambridge Healthtech Institutes- PEPTALK. January 18, 2015

San Diego, CA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Banbury Center, Cold Spring Harbor Laboratory Lewy Body Dementia: Current Status, Future Directions. November 18, 2014

Cold Spring Harbor, NY

Society for Neuroscience
Neuropore researchers presented findings on NPT200-11 at the annual Society for Neuroscience Meeting.  
November 15th-19th, 2014

  • Biophysical characterization of the interaction of NPT200-11 with alpha-synuclein.
  • Live imaging of alpha-synuclein aggregates in the retina of alpha-synuclein-GFP transgenic mice as a marker of alpha-synuclein pathology in the brain.
  • The novel alpha-synuclein stabilizer NPT200-11 improves behavior, neuropathology, and biochemistry in the murine thy1-ASYN transgenic model of Parkinson’s disease.
  • The novel alpha-synuclein stabilizer NPT200-11 reduces retinal deposits of ASYN-eGFP in a transgenic mouse model of Parkinson’s disease/Lewy body disease. 

Washington, DC

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 9th Annual Genetics Epidemiology of Parkinson’s Disease Consortium. September 12, 2014

Vancouver, BC, Canada

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Nutricia Symposium Alzheimer’s Association International Conference 2014. July 12, 2014

Copenhagen, Denmark

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the International Parkinson and Movement Disorder Society 18th International Congress. June 10, 2014

Stockholm, Sweden

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Keystone Symposia. April 16, 2014

Keystone, CO

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of North Texas Health Science Department of Cell Biology and Immunology. April 10, 2014

Fort Worth/Dallas, TX

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 13th International Symposium of Advances in Alzheimer Therapy. March 27, 2014

Geneva, Switzerland

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of Omaha. NeuroAIDS, Other Neurodegenerative Disorders and Mental Health – The Role of Brain Banks. March 21, 2014

Omaha, NE

Society for Neuroscience
Neuropore researchers presented at the annual Society for Neuroscience Meeting.
In vivo two-photon imaging of alpha-synuclein: Effects of a novel alpha-synuclein stabilizer in an eGFP-alpha-synuclein transgenic mouse model of Lewy Body disease.
Retinal scanning evaluations of alpha-synuclein-eGFP deposition in a transgenic mouse model of PD/DLB.
November 9th-13th, 2013

San Diego, CA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of Pennsylvania Annual Marian S Ware Neurodegenerative diseases Retreat. Transmission of Neurodegenerative Disease Pathologies. October 25, 2013

Philadelphia, PA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Expanding Prion Horizons 2013 Symposium. October 18, 2013

Fort Collins, CO

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the First International Novartis Parkinson’s Disease Symposium. September 14, 2013

Osaka, Japan

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Tokyo Metropolitan Institute of Medical Science Neurosciences Symposium. September 10, 2013

Tokyo, Japan

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Luxembourg Centre for Systems Biomedicine, & University of Luxembourg. May 21, 2013

Luxembourg

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Ever Neuropharma Elan Symposium. April 26, 2013

San Diego, CA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Functional Genomics of Parkinson's Disease and beyond Symposium. April 18, 2013

Tubingen, Germany

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Society of NeurolImmune Pharmacology 19th SNIP Scientific Conference. April 6, 2013

San Juan, Puerto Rico

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 11th International Conference on Alzheimer's and Parkinson's Disease. March 8, 2013

Florence, Italy

Neuropore researchers presented at International Conference on AD/PD.  Development of a Novel Series of PI3K Modulators Designed to Promote Autophagy and the Cellular Clearance of Neurotoxic Peptides. March 6th-10th, 2013

Florence, Italy

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Michael J Fox Foundation Therapeutics Program Review. February 26, 2013

New York, NY

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 6th International Winter Conference on Alzheimer’s disease. December 9, 2012

Zuers, Austria

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Department of Neurology University of Louisville. The Roth Lecture. November 16, 2012

Louisville, KY

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of Melbourne Brain Symposium. The John Cade Lecture. November 1, 2012

Melbourne, Australia

Neuropore researchers presented findings at the annual Society for Neuroscience Meeting. Novel organic compound targeting misfolded α-synuclein normalized calcium abnormalities in α-synuclein transgenic Parkinson’s Disease-like mouse model. October 13th-17th, 2012

New Orleans, LA

Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 100 years of Lewy Bodies Conference. September 15, 2012

Munich, Germany

Alzheimer's Association International Conference
Neuropore researchers presented at the AAIC Meeting.
Neuroprotective effects of a novel abeta-protein stabilizer in an APP transgenic mouse model of Alzheimer’s disease. July 14th-19th, 2012

Vancouver, BC

Society for Neuroscience Neuropore researchers presented findings on NPT100-18A at the annual Society for Neuroscience Meeting. Novel structure based designed compound reduces accumulation of toxic alpha-synuclein and improves deficits in a transgenic murine model of PD/DLB. November 12th-16th, 2011